戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  were changes in medication/nonadherence and supraventricular arrhythmia.
2 phy that could explain an increased risk for supraventricular arrhythmia.
3 to that of the human, including induction of supraventricular arrhythmia.
4  months and before recurrence of symptomatic supraventricular arrhythmia.
5 t recurrence of a symptomatic ECG-documented supraventricular arrhythmia.
6 pleted follow-up or documented a symptomatic supraventricular arrhythmia.
7 ent of specific therapies for other forms of supraventricular arrhythmia.
8  focus on decreases in ejection fraction and supraventricular arrhythmia.
9         Atrial fibrillation (AF) is a common supraventricular arrhythmia.
10 ed in 17 subjects because of hypertension or supraventricular arrhythmias.
11 rt surgery to control 2 common postoperative supraventricular arrhythmias.
12  used to control the ventricular response to supraventricular arrhythmias.
13 ion, including particulate matter, may cause supraventricular arrhythmias.
14 e that air pollution is also associated with supraventricular arrhythmias.
15   The CS has been implicated in a variety of supraventricular arrhythmias.
16 n the range previously reported for standard supraventricular arrhythmias.
17 edications and the recurrence of symptomatic supraventricular arrhythmias.
18 s a basis for localized AV nodal reentry and supraventricular arrhythmias.
19 bnormalities suggestive of susceptibility to supraventricular arrhythmias.
20 n defects, left ventricular dysfunction, and supraventricular arrhythmias.
21 roved for the treatment of heart failure and supraventricular arrhythmias.
22 ly hazard of increased neurologic events and supraventricular arrhythmias.
23 1] and 1.13 (95% CI 1.05-1.22; P = .001) for supraventricular arrhythmias, 1.09 (95% CI 1.01-1.19; P
24 n our study, 14 (93%) manifested arrhythmia: supraventricular arrhythmia (13 of 15), including sick s
25 e salbutamol group had a higher incidence of supraventricular arrhythmias (26 vs. 10%; p = 0.2).
26 ad a history of atrial fibrillation or other supraventricular arrhythmia, 510 had an implantable card
27 on disturbances (61% and 44%, respectively), supraventricular arrhythmias (69% and 52%, respectively)
28 arrhythmia, 7.79% (95% CI, 4.87%-11.27%) for supraventricular arrhythmia, 8.68% (95% CI, 2.26%-17.97%
29  the right atrium caused repeated attacks of supraventricular arrhythmia and a strikingly reduced car
30 ts had at least one catheter ablation; 5 for supraventricular arrhythmias and 2 for ventricular arrhy
31 otein levels and determine susceptibility to supraventricular arrhythmias and changes in cardiac stru
32 ycoprotein progranulin on the development of supraventricular arrhythmias and changes to cardiac func
33 y be valuable for the long-term treatment of supraventricular arrhythmias and control of ventricular
34                                          The supraventricular arrhythmias and their treatment are des
35  developed atrial fibrillation, 2 (5%) other supraventricular arrhythmias, and 10 (25%) were diagnose
36 ibrillation/flutter, bradyarrhythmias, other supraventricular arrhythmias, and ventricular arrhythmia
37                                              Supraventricular arrhythmias are frequently encountered
38               Co-primary study outcomes were supraventricular arrhythmias, bradyarrhythmias, and vent
39 anding of how this molecular defect leads to supraventricular arrhythmias could influence the develop
40                                              Supraventricular arrhythmias developed over lifetime in
41                              Ventricular and supraventricular arrhythmias, heart failure events, redu
42 chycardia represents the most common regular supraventricular arrhythmia in humans, and catheter abla
43                                          The supraventricular arrhythmias include a wide spectrum of
44 y has been implicated in the pathogenesis of supraventricular arrhythmias, including atrial fibrillat
45                                              Supraventricular arrhythmias (junctional ectopic tachyca
46    Children with incessant tachyarrhythmias (supraventricular arrhythmias [n=26], junctional ectopic
47 essor exposure may also decrease the risk of supraventricular arrhythmia (odds ratio, 0.55; 95% CI, 0
48 use, and the first inappropriate shock for a supraventricular arrhythmia or death from any cause.
49  of skeletal muscle involvement (p < 0.001), supraventricular arrhythmia (p = 0.003), conduction defe
50 in the two groups, but neurologic events and supraventricular arrhythmias remained more frequent in t
51  available on risk factors for perioperative supraventricular arrhythmia (SVA) after noncardiac surge
52 inib was associated with higher reporting of supraventricular arrhythmias (SVAs) (ROR: 23.1; 95% conf
53 t tachycardia is an infrequently encountered supraventricular arrhythmia that continues to present di
54  Atrial fibrillation (AF) is the most common supraventricular arrhythmia that, for unknown reasons, i
55 nhibition shows promise for the treatment of supraventricular arrhythmias, the absence of subtype-sel
56                                              Supraventricular arrhythmia was associated with a 33% in
57                 The recurrence rate of total supraventricular arrhythmias was significantly lower in
58             Left ventricular dysfunction and supraventricular arrhythmia were the most commonly repor
59 trial dilatation up to giant size; (3) early supraventricular arrhythmias with progressive loss of at